Merck & Co., Inc. stock (US58933Y1055): Cancer drug momentum and recent approvals keep focus on pipeline

Merck & Co., Inc. stock remains in focus as the Keytruda maker expands its oncology franchise with recent regulatory approvals and combination data, while investors weigh patent timelines, pricing risks and the broader US healthcare backdrop.

Merck & Co., Inc. stock is closely watched by healthcare investors as the US pharma group continues to expand its oncology portfolio around flagship immunotherapy Keytruda, while navigating pricing pressure debates and looming patent expirations in the coming years. Recent regulatory approvals and label expansions have reinforced the importance of Merck’s cancer franchise for both revenue growth and long-term strategic positioning.

As of: 28.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Merck & Co.
• Sector/industry: Pharmaceuticals, biotechnology
• Headquarters/country: United States
• Core markets: Oncology, vaccines, hospital acute care, animal health
• Key revenue drivers: Cancer drug Keytruda, vaccines such as Gardasil, animal health portfolio
• Home exchange/listing venue: New York Stock Exchange (ticker: MRK)
• Trading currency: US dollar (USD)

Merck & Co., Inc.: core business model

Merck & Co., Inc. is a large US-based pharmaceutical company with a diversified portfolio across human health and animal health, and a strategic focus on innovative prescription medicines. The group generates most of its revenue from patented drugs, vaccines and hospital products that are prescribed by physicians and reimbursed by public or private payers in key markets such as the United States, Europe and parts of Asia.

The company’s business model rests on extensive research and development spending to discover and develop new therapies, combined with global manufacturing and a sizable commercial infrastructure. In practice, Merck invests heavily in oncology, vaccines and specialty medicines, aiming to bring differentiated products through clinical trials and regulatory approvals. Once launched, products are marketed to healthcare professionals and institutions, with Merck often partnering with hospitals, oncologists and national health systems to ensure access.

Like other major pharmaceutical groups, Merck faces a limited period of market exclusivity for each patented medicine. After key patents expire, generic or biosimilar competitors typically enter the market, reducing prices and eroding sales. This dynamic creates an ongoing need for pipeline replenishment: revenue from mature products is used to fund the next generation of therapies. The success of this cycle over time largely determines the company’s growth profile, margin structure and ability to return cash to shareholders through dividends and buybacks.

Merck also operates a meaningful animal health division, which sells vaccines and therapeutics for livestock and companion animals. This segment diversifies the group’s revenue base and is less exposed to some of the policy debates that affect human drug pricing. Nevertheless, the human health business, led by oncology and vaccines, remains the primary earnings driver and tends to dominate investor attention when assessing the stock.

Main revenue and product drivers for Merck & Co., Inc.

The single most important revenue driver for Merck in recent years has been Keytruda, an immune checkpoint inhibitor that targets the PD-1 pathway and is used in multiple cancer types. Keytruda has gained numerous approvals as a monotherapy and in combination regimens across indications such as lung cancer, melanoma and certain gastrointestinal and genitourinary cancers. These label expansions have helped the drug become a cornerstone therapy in oncology and a central pillar of Merck’s financial performance.

Alongside Keytruda, Merck’s vaccine portfolio plays a key role in its revenue mix. The human papillomavirus vaccine Gardasil is widely used for the prevention of HPV-related diseases and has seen uptake in many countries. Other vaccines target diseases such as shingles and certain pediatric infections. These products provide relatively stable demand profiles, as vaccination programs tend to be recurrent and often supported by public health initiatives and immunization schedules.

Merck’s hospital acute care and specialty products add another layer of diversification. These include anti-infectives, cardiovascular and endocrine therapies, as well as anesthetics and other medicines used in inpatient settings. While often smaller in revenue than flagship oncology products, such portfolios can contribute to steady cash flows and help balance the impact of patent cliffs in other areas.

The animal health business contributes with products ranging from vaccines for cattle and swine to parasiticides for companion animals. The segment benefits from trends such as growing global protein consumption and rising spending on pet healthcare in developed markets. For investors, animal health is sometimes viewed as a more defensive component of Merck’s earnings profile, with somewhat different regulatory and reimbursement dynamics compared with human pharmaceuticals.

Over the medium term, Merck’s growth will likely be shaped by how effectively the company can extend Keytruda’s lifecycle, bring next-generation oncology agents to market and expand its vaccines and specialty franchises. Investors also monitor business development activities, such as licensing deals and acquisitions, as tools for complementing the internal pipeline and addressing therapeutic areas where Merck sees strategic gaps.

Conclusion

Merck & Co., Inc. stock represents exposure to a major US pharmaceutical group with a strong oncology franchise, led by Keytruda, and supported by vaccines, hospital products and animal health. The company’s prospects are closely tied to the continued success of its cancer portfolio, the ability to manage patent expirations and pricing debates, and progress in advancing new therapies through its pipeline. For US-focused investors, Merck’s New York listing, dollar-denominated earnings and participation in key healthcare indices reinforce its relevance when considering large-cap healthcare exposure.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.